Hikal valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.08×————
1.44×————
16.22×————
Enterprise multiples
1.83×————
13.64×————
48.58×————
Yield
−1.4%————
6.2%————
Reference — adjusted share basis
₹202.10————
−₹2.74−₹3.95₹7.35₹5.64₹6.35
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

HIKAL₹202.10

Hikal Limited

· Pharma & Health
₹ CrorePeersPANACEABIODCALSAIPARENTINDOCOSOLARAWINDLASINDSWFTLABHESTERBIOMcap ₹2,496 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/B————2.08
P/Sales————1.44
Price to Free Cash Flow————16.22
Enterprise Multiples
EV/Sales————1.83
EV/EBITDA————13.64
EV/EBIT————48.58
Yield
Earnings Yield %————-1.35
FCF Yield %————6.17
Reference — adjusted share basis
Price (FY-end close, adj.)————202.10
EPS (adj.)6.355.647.35-3.95-2.74
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.